Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in moderate to severe plaque psoriasis
NCT01483599Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2011
- Primary completion
- Nov 2012
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of guselkumab in plaque psoriasis (7 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at 16 weeks. Started Nov 2011; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01483599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01483599.